Skip to content

Splenopentin

A five-residue fragment of splenin, the spleen's near-twin of thymopoietin, differing from thymopentin by a single atom's worth of chemistry — glutamate instead of aspartate at position 34 — and behaving differently because of it. Its acetylated form, Berlopentin, reached Phase I and controlled clinical trials in East Germany before the country that was developing it ceased to exist.

DPreliminaryLimited Data
Last updated 22 citations
TL;DR

Splenopentin is thymopentin's one-residue sibling, and the founding comparison between them is titled for their contrasting activities, not their similarity. Thymopentin affects neuromuscular transmission and pushes T-cell precursors to differentiate while blocking the same induction in B-cells; splenopentin does neither of the first two and induces both lineages. Where thymopentin did nothing to human bone-marrow colony formation, splenopentin co-stimulated it alongside GM-CSF and protected marrow against AZT toxicity. The common description of the two as paired or parallel immunomodulators gets this backwards. The other thing usually said about splenopentin — that it never reached humans — is also wrong. Its serum-stable diacetyl form was developed by VEB Berlin-Chemie as Berlopentin and went through a Phase I study, two controlled trials and a randomised drug-interaction study at Jena between 1989 and 1992: 50 mg three times a week, well tolerated, with no effect on seven hormones or on caffeine clearance. In hay fever the intravenous route beat placebo and the subcutaneous route did not. In psoriatic arthritis, twelve months of it relieved symptoms while the x-rays got worse, and the authors concluded it was not sufficient as a sole therapy. Then the GDR dissolved, and the programme stopped. No registry record exists because it predates the registries, and no evidence has been found that it was ever marketed anywhere.

What is Splenopentin?

Splenopentin (SP-5) is the pentapeptide Arg-Lys-Glu-Val-Tyr, corresponding to residues 32 to 36 of splenin. Splenin is the spleen-derived polypeptide that Gideon Goldstein's group at Memorial Sloan Kettering and Ortho identified as a close relative of the thymic hormone thymopoietin — so close that it was originally catalogued as thymopoietin III, and so close that the two 49-residue proteins differ at a single position. Thymopoietin carries aspartate at residue 34; splenin carries glutamate. The complete bovine sequences were published in 1981, and the pentapeptide active fragments of each were compared in 1984. A naming correction is worth making at the outset, because the error is widespread and it propagates: the parent protein is splenin, not splenopoietin. There is no such molecule as splenopoietin — the term returns nothing in PubMed and appears in no nomenclature record. Splenopentin's own entries list it as splenin pentapeptide (32-36) and thymopoietin III pentapeptide (32-36), under CAS registry number 75957-60-7. Most of what has actually been studied is not splenopentin itself but its diacetylated derivative, DA SP-5, in which the arginine and lysine side chains are acetylated. This is not a cosmetic difference. Native splenopentin is hydrolysed from its N-terminus in human serum; the acetylated form is attacked at the C-terminus instead, and the change in degradation route is why the acetylated version was the one taken into development. Under the trade name Berlopentin and the development code BCH 069, it was a VEB Berlin-Chemie compound in the German Democratic Republic, with its own patents and its own clinical programme.

What Splenopentin Is Investigated For

Splenopentin is a discontinued development compound rather than a research chemical that never left the bench, and the distinction matters for how its evidence should be read. Its diacetyl form was taken through a real clinical programme at Friedrich Schiller University in Jena between 1989 and 1992, sponsored by VEB Berlin-Chemie, and the results are indexed and readable. What that programme found was mixed and mostly honest. A Phase I study gave 50 mg subcutaneously three times weekly for four weeks, or 50 mg intravenously for six weeks, and concluded the drug was well tolerated; a companion endocrine study found no effect on prolactin, luteinising hormone, TSH, cortisol, testosterone, progesterone or estradiol, and a randomised study found no effect on caffeine clearance, which is the classic probe for hepatic oxidative metabolism. In seasonal allergic rhinitis the intravenous route was significantly better than placebo at reducing symptoms and blunted the seasonal rise in grass-pollen-specific antibodies, while the subcutaneous route was not effective — an unusually clean route-dependence that any future work would have to reckon with. In psoriatic arthritis, eight patients treated for twelve months had symptomatic improvement while radiographs showed the disease worsening, and the investigators concluded that splenopentin alone is not a sufficient therapeutic drug. The preclinical core is haematopoietic rather than anti-inflammatory. Splenopentin accelerated restoration of myelopoietic and immune function after sublethal irradiation in mice, accelerated antibody formation after syngeneic bone-marrow transplantation, and acted in human bone-marrow cultures as a co-stimulant for GM-CSF that also preserved colony formation against the toxicity of zidovudine. Its behaviour in graft-versus-host reaction is genuinely two-sided and is the clearest reason not to treat it as a benign immune tonic: in one strain combination it prevented GVHR-induced immunodeficiency and suppressed anti-DNA autoantibodies, while in another it dramatically enhanced the reaction to the point of high mortality. There is no approved product anywhere, nothing in any trial registry, and no evidence that it was ever marketed. Material sold under the name through research channels is unregulated and has no validated human use.

One-residue sibling of thymopentin with contrasting rather than parallel immunological activity
Moderate70%
Co-stimulation of human bone-marrow colony formation with GM-CSF, and protection of marrow against AZT toxicity in vitro
Preliminary30%
Acceleration of immune and myelopoietic recovery after irradiation and bone-marrow transplantation in mice
Preliminary30%
Reached Phase I and controlled clinical trials in East Germany as Berlopentin before the programme ended
Preliminary30%
Never marketed, never registered, and absent from every modern trial registry
Moderate70%

History & Discovery

The sequence of events runs earlier than most accounts of splenopentin suggest. In 1981 Audhya, Schlesinger and Goldstein published the complete amino acid sequences of bovine thymopoietins I, II and III in Biochemistry, and the third of those was a polypeptide newly isolated from spleen rather than thymus. It was 49 residues long, showed minor heterogeneity at residue 34, and was close enough to the thymic hormone to be catalogued as a thymopoietin. It was later named splenin, and the single-residue difference — glutamate for aspartate at position 34 — turned out to be the whole story. In 1984 the same laboratory published the comparison that gave splenopentin its name and its meaning. The pentapeptide fragments of each parent protein, residues 32 to 36, were tested side by side, and the paper was titled for the contrast rather than the similarity. Thymopoietin and thymopentin affected neuromuscular transmission and induced T-precursor differentiation while inhibiting it in B-lineage cells; splenin and splenopentin did neither of the first two and induced both lineages. A companion study in mouse skin grafting that year found thymopentin correcting the rejection response of thymectomised females where splenopentin did not. Both peptides came out of the same programme — Goldstein's group with Audhya, Scheid and Boyse, between Memorial Sloan Kettering and Ortho — and not from separate thymic and splenic research efforts, as is sometimes implied. The development chapter belongs to East Germany. VEB Berlin-Chemie took the diacetylated derivative, in which the arginine and lysine side chains are acetylated to redirect serum degradation away from the N-terminus, and developed it as BCH 069, later Berlopentin, with patents filed from 1988. The clinical work was done at Friedrich Schiller University in Jena and published between 1989 and 1992: a Phase I study, a controlled trial in hay fever, a randomised caffeine-interaction study, an endocrine safety study, a twelve-month series in psoriatic arthritis, and a validated plasma immunoassay to support them. The dosing settled at 50 mg three times a week. Then the state that was funding it stopped existing. The German Democratic Republic dissolved in October 1990, in the middle of the trial window, and VEB Berlin-Chemie was privatised. The last Berlopentin papers appear in 1992 and 1993 and nothing followed. The compound was never approved or marketed, so far as any reachable register shows, and the final splenopentin paper of any kind was published in 2006 — a receptor-binding study that used it as a comparator for thymopentin rather than studying it in its own right. One historical caveat deserves stating plainly, because it touches a fact often repeated about this molecule. The human form of splenin and splenopentin is widely given as having alanine at position 34, making human splenopentin Arg-Lys-Ala-Val-Tyr. That sequence traces to a 1987 PNAS paper on the isolation and complete amino acid sequence of human thymopoietin and splenin, and that paper was retracted in 1994 as part of a larger retraction affecting the programme. The 1981 bovine sequences and the 1984 splenopentin comparison are not affected. This page therefore gives splenopentin as the bovine-derived Arg-Lys-Glu-Val-Tyr, the sequence carried by every nomenclature record and by the primary pharmacology, and does not assert a human sequence.

How It Works

Your thymus and your spleen each make a signalling protein that tells immature immune cells what to become, and the two proteins are almost identical — they differ at a single spot. Splenopentin is a five-amino-acid piece cut from the spleen version, the way thymopentin is cut from the thymus version. Despite the near-identical chemistry they do not do the same things: the thymus fragment pushes cells toward becoming T-cells and holds back B-cells, while the spleen fragment pushes both. The spleen fragment is also the one that helps bone marrow recover — it works alongside growth factors to restore blood-cell production after radiation or marrow transplant, which the thymus fragment does not do. A more stable, acetylated version was developed as a drug in East Germany in the late 1980s and tested in people for hay fever and arthritis. It worked for hay fever when injected into a vein but not under the skin, and it was not enough on its own for arthritis. The country developing it dissolved, and the work stopped.

Splenopentin is Arg-Lys-Glu-Val-Tyr, residues 32 to 36 of splenin. Splenin and thymopoietin are 49-residue polypeptides differing at one position — glutamate against aspartate at residue 34 — and the pentapeptide fragments inherit that single substitution. Given how small the chemical difference is, the divergence in activity is the striking finding, and it is the finding the founding literature was built around. The 1984 comparison established the pattern. Thymopoietin and thymopentin affect neuromuscular transmission and induce phenotypic differentiation of T-cell precursors in vitro while inhibiting the differentiative induction of B-cells. Splenin and splenopentin do not affect neuromuscular transmission, and they induce both T- and B-cell precursors. The same year, work in mice showed that both peptides heightened the male-skin-graft rejection response of intact young females, but only thymopentin lowered the elevated response of thymectomised females — splenopentin did not. The two nonetheless appear to act at a common site: in binding studies using fluorescently labelled thymopentin, thymopentin and human splenopentin were nearly equipotent inhibitors of binding to the thymopoietin receptor. The haematopoietic activity is where splenopentin separates most clearly from its sibling. In human bone-marrow cultures, diacetyl-splenopentin acted as a co-stimulant for recombinant GM-CSF in inducing colony formation, and marrow exposed to it before zidovudine and GM-CSF produced a colony-forming response similar to GM-CSF alone — that is, it preserved marrow function against the drug's toxicity. Thymopentin, tested in the same system, did not influence colony formation. A separate study using stromal cultures found that splenopentin alone had only marginal activity but potentiated GM-CSF, serving as an additional proliferative signal with negligible effect on cell maturation, which sets a reasonable ceiling on the claim. In vivo, the peptide accelerated restoration of myelopoietic and immune function after sublethal irradiation in mice and accelerated antibody formation after syngeneic bone-marrow transplantation, with the optimisation work finding that only continuous treatment produced complete reconstitution of antibody formation. Its effect on graft-versus-host reaction runs in both directions depending on the strain combination, prevention of GVHR-induced immunodeficiency and of anti-DNA autoantibody production in one setting, dramatic enhancement of the reaction with high mortality in another. Two pharmacological details explain the form that was developed. Splenopentin in human serum is degraded by hydrolysis of peptide bonds in its N-terminal region, while the N-acetylated peptide is cleaved at the C-terminal end instead; aminopeptidase N, which hydrolyses splenopentin, thymopentin, tuftsin and rigin from the N-terminus, is the enzyme that makes the native peptide short-lived. Acetylating the arginine and lysine side chains redirects degradation and is the reason the diacetyl form carried the clinical programme. One further effect resists a simple description. The response of human lymphocytes to diacetyl-splenopentin depends on donor age: stimulated proliferation was inhibited in young donors, further increased in old donors, and unchanged in newborns. Bovine and human splenopentin also behaved differently in the same system, with the bovine form failing to increase phytohaemagglutinin-induced transformation where the human form did.

Evidence Snapshot

Overall Confidence25%

Human Clinical Evidence

Small, old, and real. Between 1989 and 1992 the diacetyl form, BCH 069 or Berlopentin, went through a Phase I study (50 mg three times weekly, subcutaneous for four weeks or intravenous for six, concluded well tolerated), a controlled trial in hay fever (intravenous significantly superior to placebo on symptoms and on the seasonal rise in grass-pollen-specific antibodies; subcutaneous not effective), a randomised drug-interaction study (no effect on caffeine elimination), an endocrine safety study (no effect on seven hormones), and a twelve-month open series of eight patients with psoriatic arthritis (symptomatic improvement with radiographic worsening; the authors concluded it was not sufficient as a sole therapy). Nothing has been published since. No regulator approved it and nothing appears in any modern trial registry, which is expected for a programme that ended before those registries existed.

Animal / Preclinical

Substantially larger than the page previously implied — roughly two dozen primary papers, concentrated in the GDR and Soviet literature between 1986 and 1993. The main threads are immune and myelopoietic reconstitution after irradiation and bone-marrow transplantation, antibody formation in immunosuppressed mice, bidirectional effects on graft-versus-host reaction, Langerhans cell recruitment, antigen-induced arthritis in rabbits, and scattered reports in alcohol-induced immunodeficiency, learning and memory, and pre-challenge protection against foot-and-mouth disease virus. Two tumour studies found no effect on metastasis formation or on antileukaemic activity.

Mechanistic Rationale

Reasonable and specific. The single-residue relationship to thymopentin is established by complete sequences, the divergent activity profile is the subject of the founding paper, the shared thymopoietin receptor is supported by binding data, and the serum-degradation work explains why the acetylated form was the one developed. What is missing is any modern molecular follow-up: the signalling downstream of the receptor has not been worked out, and essentially nothing has been published on this peptide since 2006.

Research Gaps & Open Questions

What the current literature has not yet settled about Splenopentin:

  • 01Whether anything in the Berlopentin programme would replicate. Two controlled trials, a Phase I study and a randomised interaction study were completed to a reasonable standard for their era and then simply stopped when the sponsoring state dissolved. None has been repeated in thirty-five years, and the hay fever result in particular — intravenous significantly better than placebo, subcutaneous ineffective — is both specific and unexplained.
  • 02Why the route dependence exists. A peptide that works intravenously and not subcutaneously at the same dose implies something about absorption, degradation or the kinetics required for effect, and nobody followed it up.
  • 03What determines the direction of the graft-versus-host effect. The same compound prevented GVHR-induced immunodeficiency in one strain combination and dramatically enhanced the reaction with high mortality in another, which is the kind of divergence that usually reflects an identifiable variable. The original investigators said as much and the question was never answered.
  • 04Why splenopentin supports myelopoiesis when thymopentin does not, given a one-residue difference and an apparently shared receptor. The two peptides are nearly equipotent at the thymopoietin receptor in binding assays, yet only splenopentin co-stimulates human bone-marrow colony formation. Either the shared receptor is not the one doing this work, or the substitution changes signalling downstream rather than binding.
  • 05Whether the age-dependence of the lymphocyte response is real and reproducible. Inhibition in young donors, enhancement in old donors and no effect in newborns is a striking pattern from a single group, never independently tested, and it would matter for any population the peptide was aimed at.
  • 06Whether a human sequence exists at all. The widely repeated human form, with alanine at position 34, rests on a paper that was retracted in 1994, and no replacement determination has been published.

Forms & Administration

There is no marketed product. In the clinical programme the compound used was the diacetylated derivative rather than native splenopentin, given as a 50 mg dose either subcutaneously or by intravenous injection, and the distinction between those routes was not trivial — in the hay fever trial the intravenous route beat placebo and the subcutaneous route did not. The dilution mattered too: a flush or heat sensation accompanied 50 mg given in 10 mL but not the same dose in 20 mL. Native splenopentin is cleaved rapidly from its N-terminus in human serum, which is why the acetylated form was developed, so research material sold as plain splenopentin is not the molecule that was given to patients. A plasma enzyme immunoassay was developed for the programme; this page has not read that paper and cites it for nothing beyond the assay's existence.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Typical Range

50 mg per dose of the diacetylated derivative in the East German clinical programme. No dose for native splenopentin has ever been established in humans, and no approved product exists anywhere.

Frequency

Three times weekly — four weeks subcutaneously or six weeks intravenously in the Phase I study, and twelve months in the psoriatic arthritis series.

Timing Considerations

No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.

Protocol Notes

Two details from that programme matter more than the number. The first is route: in the hay fever trial the intravenous arm was significantly better than placebo while the subcutaneous arm was not effective, so route was not interchangeable in the one controlled efficacy test the compound has. The second is that the drug given was diacetyl-splenopentin, not splenopentin. Native splenopentin is hydrolysed from its N-terminus in human serum; acetylating the arginine and lysine side chains moves degradation to the C-terminal end, and that modification is the reason the compound was developable at all. Research material sold as splenopentin is therefore not the substance any of these figures describe. There is no contemporary prescribing information for any of this, in any language. The regimen above is a historical record of an abandoned development programme, not a protocol, and the longest exposure anyone has documented ended with radiographic disease progression.

Splenopentin has never been approved by any regulator and has never been marketed. Nothing here constitutes a usable dosing protocol.

Common Questions

What is splenopentin?

Splenopentin (SP-5) is the five-residue peptide Arg-Lys-Glu-Val-Tyr, corresponding to residues 32 to 36 of splenin — the spleen's counterpart to the thymic hormone thymopoietin, which it matches everywhere except position 34. It was identified in 1984 in the course of comparing the two parent proteins' active fragments. Its acetylated derivative was developed as a drug candidate in East Germany under the name Berlopentin and reached human trials, but it was never approved or marketed anywhere and no product exists today.

How is splenopentin different from thymopentin?

Chemically by one residue: thymopentin is Arg-Lys-Asp-Val-Tyr, splenopentin is Arg-Lys-Glu-Val-Tyr, glutamate where thymopentin has aspartate. Biologically the difference is larger than that implies, and the literature is explicit about it — the founding comparison from Goldstein's group is titled for the contrasting activities of the two parent molecules. Thymopoietin and thymopentin affect neuromuscular transmission and induce T-cell precursors to differentiate while inhibiting the equivalent induction in B-lineage cells. Splenin and splenopentin do not affect neuromuscular transmission, and they induce both T- and B-cell precursors. In mice, thymopentin lowered the heightened male-skin-graft rejection response of thymectomised females and splenopentin did not. In human bone-marrow culture, splenopentin co-stimulated colony formation with GM-CSF where thymopentin had no effect at all. They also appear to share a receptor: the two are nearly equipotent at displacing labelled thymopentin from the thymopoietin receptor. Describing them as paired or parallel immunomodulators, which is common, inverts the finding that defined them.

Has splenopentin ever been given to humans?

Yes, which is contrary to how it is usually described. The diacetylated form, BCH 069 or Berlopentin, was developed by VEB Berlin-Chemie and tested at Friedrich Schiller University in Jena. A Phase I study dosed 50 mg three times weekly subcutaneously for four weeks or intravenously for six weeks and reported it well tolerated. A controlled trial in hay fever found intravenous treatment significantly better than placebo, with subcutaneous treatment ineffective. A randomised study established that it does not interfere with caffeine clearance, and a separate study found no effect on seven circulating hormones. A twelve-month open series in psoriatic arthritis found symptomatic benefit alongside radiographic worsening. The programme ran from roughly 1989 to 1992 and did not continue; the German Democratic Republic, whose state pharmaceutical enterprise was developing it, dissolved in October 1990 in the middle of that window.

Is splenopentin approved or sold as a medicine anywhere?

No. No regulator has approved splenopentin or Berlopentin, and this page found no evidence it was ever brought to market, including in the GDR or reunified Germany — though an absence of records in reachable registers is weaker evidence than a positive statement would be. It appears in no entry on ClinicalTrials.gov under any of its names, which is unsurprising given that its clinical programme predates the registry. Material sold through research-chemical channels has no validated clinical use, no human dosing basis outside the Jena protocol, and no quality control over identity or purity.

Does splenopentin boost natural killer cells?

This claim circulates and it misreads the paper behind it. A 1993 study in FEBS Letters tested splenopentin and a series of synthetic analogues for effects on human natural killer cell activity. Two of the analogues significantly augmented NK activity in vitro — splenopentin itself did not. The same paper reported that none of the compounds affected lymphocyte proliferative responses. Claims that splenopentin augments NK cells are attributing its analogues' activity to the parent peptide.

Who Splenopentin Is NOT For

Contraindications
  • •Research peptide with no approved clinical use and no modern safety data — not appropriate for self-administration under any circumstances
  • •Patients undergoing or being prepared for allogeneic bone-marrow or stem-cell transplantation. This is not a theoretical concern: in one mouse strain combination splenopentin dramatically enhanced the graft-versus-host reaction with high mortality, and the investigators explicitly said predictive parameters would be needed before any human transplant use
  • •Patients with autoimmune disease or active malignancy — the peptide induces both T- and B-lineage precursors rather than T-cells alone, and two tumour studies found it did not reduce metastasis formation or improve antileukaemic treatment
  • •Older adults should not assume the direction of effect seen in younger subjects: lymphocyte proliferation responses to this peptide were inhibited in young donors and increased in old donors
  • •Pregnancy and lactation — no safety data of any kind

Drug & Supplement Interactions

One formal interaction study exists, which is one more than most peptides at this tier have. A randomised study found that treatment with Berlopentin did not significantly affect caffeine elimination, from which the authors concluded that the clearance of drugs biotransformed by hepatic microsomal oxidation is unlikely to be affected by co-administration. That is a meaningful negative: it covers the main route by which small molecules interfere with one another, and it is consistent with a pentapeptide cleared by peptidases rather than by cytochrome enzymes. A companion study found no effect on seven circulating hormones, which rules out the endocrine interactions that somatostatin-family peptides raise. The interactions that would matter are pharmacodynamic and have not been studied. Splenopentin was characterised as a co-stimulant rather than a primary signal — it potentiated GM-CSF in human marrow cultures while doing little alone — so its behaviour alongside haematopoietic growth factors, cytotoxic chemotherapy or antiretrovirals is the obvious question, and the zidovudine work is the only datapoint. Combination with immunosuppressive regimens runs against the peptide's direction of effect, and the graft-versus-host findings make that pairing specifically hazardous.

Safety Profile

Safety Information

Common Side Effects

A flush or heat sensation was reported when 50 mg was given intravenously in 10 mL, but not when the same dose was given in 20 mLTransient falls in triglycerides, transaminases and haemoglobin and a rise in lipase were recorded in the Phase I study, all remaining within normal reference rangesNo effect was found on prolactin, luteinising hormone, TSH, cortisol, testosterone, progesterone or estradiol

Cautions

  • • Research peptide — no regulator has approved splenopentin for any indication, and no product has ever been marketed
  • • The human safety data consist of one Phase I study and a handful of small controlled trials, all conducted between 1989 and 1992, none repeated since
  • • The effect on graft-versus-host reaction in mice is bidirectional and strain-dependent: in one model it prevented GVHR-induced immunodeficiency, in another it dramatically enhanced the reaction with high mortality. The investigators concluded that parameters allowing prediction in an individual case would be needed before any human bone-marrow transplantation use
  • • Effects on human lymphocytes vary with donor age — proliferation was inhibited in young donors, increased in old donors, and unaffected in newborns — so a single expected direction of effect cannot be assumed
  • • Material sold through research-chemical channels is unregulated for identity, purity and sterility

What We Don't Know

Nothing is known about chronic exposure. The longest human experience on record is twelve months in eight patients with psoriatic arthritis, and that series reported radiographic progression despite symptomatic improvement. There is no modern pharmacovigilance data, no reproductive or developmental safety data, and no human pharmacokinetics beyond the existence of a plasma assay developed for the Berlopentin programme. The whole human record predates 1993.

Myths & Misconceptions

Myth

Splenopentin is derived from a protein called splenopoietin.

Reality

There is no such protein. The parent molecule is splenin, originally catalogued as thymopoietin III when it was isolated from bovine spleen and sequenced in 1981. The term splenopoietin returns nothing in the literature and appears in no nomenclature record; splenopentin's own entries list it as splenin pentapeptide (32-36) and thymopoietin III pentapeptide (32-36). The invented name is presumably a back-formation from thymopoietin by analogy, and it has spread widely.

Myth

Splenopentin and thymopentin are paired molecules with parallel effects.

Reality

This is the opposite of what the founding literature reports, and it is the most common error made about this peptide. The 1984 paper that established both fragments is titled for their contrasting biological activities. Thymopoietin and thymopentin affect neuromuscular transmission and induce T-cell precursors while inhibiting B-lineage induction; splenin and splenopentin do neither of the first two and induce both lineages. In mice, thymopentin corrected the rejection response of thymectomised females and splenopentin did not. In human marrow cultures, splenopentin co-stimulated colony formation and thymopentin had no effect. They differ by one residue and they do different things — which is why both were studied.

Myth

Splenopentin never reached clinical development.

Reality

It did, under a name most accounts never mention. The diacetylated form was developed by VEB Berlin-Chemie as BCH 069, trade name Berlopentin, and went through a Phase I study, a controlled trial in hay fever, a randomised drug-interaction study, an endocrine safety study and a twelve-month open series in psoriatic arthritis at Jena between 1989 and 1992. There is a validated plasma assay and there are patents. What ended the programme was not a safety finding but the dissolution of the German Democratic Republic and the privatisation of its state pharmaceutical enterprise.

Myth

Splenopentin boosts natural killer cell activity.

Reality

The paper this comes from found the opposite for splenopentin itself. Testing splenopentin against a series of synthetic analogues, two of the analogues significantly augmented human NK activity in vitro and splenopentin did not; none of the compounds affected lymphocyte proliferative responses. The finding belongs to the analogues, and attributing it to the parent peptide reverses the paper's own comparison.

Myth

Splenopentin was used to treat HIV-positive patients.

Reality

This appears in a nomenclature database scope note for Berlopentin and is not supported by any indexed study. A search for splenopentin or Berlopentin together with HIV or AIDS returns a single paper — a mouse study of Langerhans cell recruitment whose only HIV content is a speculative closing sentence suggesting the peptide might possibly be useful in such disorders. The in vitro work on protecting bone marrow against zidovudine toxicity is probably the origin of the association, but that is a study of marrow cells in culture, not of patients.

Published Research

22 studies

Chemical synthesis and application of C-terminally 5-carboxyfluorescein-labelled thymopentin as a fluorescent probe for thymopoietin receptor.

Original ResearchPMID: 17159311

Thymopentin and splenopentin as immunomodulators. Current status

Singh, Biswas, Mathur, Haq, Garg and Agarwal, Immunology Research 1998 — the standard review, and the source most responsible for the habit of discussing the two pentapeptides as a matched pair. It is a fair summary of the state of the field in 1998, but it should be read alongside the 1984 primary comparison rather than instead of it, because the framing of thymopentin and splenopentin as parallel immunomodulators obscures the divergent activities that were the reason for studying both.

ReviewPMID: 9638477

The effect of splenopentin (DA SP-5) on in vitro myelopoiesis and on AZT-induced bone marrow toxicity.

Diezel and colleagues, International Journal of Immunopharmacology 1993 — the clearest statement of what splenopentin does that thymopentin does not. Diacetyl-splenopentin acted as a co-stimulant for recombinant human GM-CSF in inducing colony formation from human bone-marrow cells, and marrow exposed to it before zidovudine responded to GM-CSF much as untreated marrow did, meaning it preserved colony formation against the drug's toxicity. Tested in the same system, thymopentin did not influence colony formation at all. The paper also states the sequence, Arg-Lys-Glu-Val-Tyr, as residues 32-36 of the splenic hormone splenin.

Original ResearchPMID: 8505137

Augmentation of human natural killer cells by splenopentin analogs.

Original ResearchPMID: 8428639

The effects of immunomodulatory thymic and splenic peptides and cyclosporin A on antigen-induced arthritis in the rat

Original ResearchPMID: 8317333

Possible action of human placental aminopeptidase N in feto-placental unit.

Original ResearchPMID: 7903813

Complete amino acid sequences of bovine thymopoietins I, II, and III: closely homologous polypeptides.

Original ResearchPMID: 7306506

Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen.

Audhya, Scheid and Goldstein, PNAS 1984 — the founding paper, and the one that makes the usual framing of splenopentin untenable. It names splenin, fixes its difference from thymopoietin at a single residue, names splenopentin as the 32-36 fragment, and reports the result its title advertises: thymopoietin and thymopentin affect neuromuscular transmission and induce T-precursor differentiation while inhibiting differentiative induction of B-lineage cells, whereas splenin and splenopentin do not affect neuromuscular transmission and induce both T- and B-cell precursors. Anything describing the two pentapeptides as parallel or comparable is contradicted by the paper that established them.

Original ResearchPMID: 6585832

Contrasting effects of thymopentin and splenopentin on the capacity of female mice to reject syngeneic male skin.

Original ResearchPMID: 6377611

[A study of enzymatic hydrolysis of splenopentin and its analogs in human serum].

Original ResearchPMID: 2751705

Splenopentin-induced reconstitution of the immune response after total body irradiation: optimization of treatment regime.

PreclinicalPMID: 2689192

Prevention of graft-vs-host reaction induced immunodeficiency by treatment with splenopentin (DAc-SP5).

PreclinicalPMID: 2624251

[Therapeutic use of splenopentin (DA SP-5) in patients with psoriasis arthropathica].

Greiner and colleagues, Dermatologische Monatsschrift 1990 — the longest human exposure on record and a candid negative. Eight patients with psoriatic arthropathy were treated for twelve months. Symptoms improved, but radiographs showed the disease worsening over the same period, and the authors concluded that splenopentin alone is not a sufficient therapeutic drug. It is the single most useful citation on the page for anyone weighing the compound's actual clinical promise.

Clinical StudyPMID: 2365110

Splenopentin (DAc-SP-5) accelerates the restoration of myelopoietic and immune systems after sublethal radiation in mice.

PreclinicalPMID: 2292457

Clinical, biochemical and immunological effectiveness of diacetyl-splenopentin (BCH 069) in hay fever.

Simon and colleagues, Allergologia et Immunopathologia 1990 — the only controlled efficacy result the compound has, and it comes with an unusually sharp route dependence. Intravenous BCH 069 was significantly superior to placebo in reducing clinical symptoms of seasonal allergic rhinitis and blunted the seasonal rise in grass-pollen-specific antibodies. Subcutaneous therapy with the same compound was not effective. Any claim about splenopentin's clinical activity that does not specify the route is leaving out the part that decided the trial.

Clinical TrialPMID: 2251976

[Age-dependent sensitivity of human lymphocytes to the immunomodulating effect of bovine and human diacetyl splenopentin].

Original ResearchPMID: 2151503

Cytofluorometric and cytomorphologic analysis of human bone marrow cells derived from stromal cultures stimulated by GM-CSF, IFN-gamma and splenopentin pentapeptide.

Original ResearchPMID: 2114995

Diacetyl-splenopentin (BCH 069) did not affect the concentrations of various hormones in men.

Original ResearchPMID: 2083571

Splenopentin (DAc-SP5)--influence on engraftment and graft-vs-host reaction after non-H-2 bone marrow transplantation in mice.

Eckert and colleagues, Experimental and Clinical Endocrinology 1990 — the reason splenopentin cannot be described as a benign immune tonic. In one strain combination the graft-versus-host reaction was dramatically enhanced, to the point of high mortality, while companion work in a different combination found the opposite. The authors' own conclusion is the appropriate caution: before any application to human bone-marrow transplantation, parameters would be needed that allow an exact prediction of the effect on the graft-versus-host reaction in each individual case.

PreclinicalPMID: 2083570

Phase-I study of diacetyl-splenopentin (BCH 069).

Simon and colleagues, Allergie und Immunologie 1990 — the study that disproves the common claim that splenopentin never reached humans. Patients received 50 mg of BCH 069 or placebo subcutaneously three times weekly for four weeks, or 50 mg intravenously for six weeks. The conclusion was that BCH 069 is a well tolerated drug. Transient changes in triglycerides, transaminases, haemoglobin and lipase stayed within normal ranges, and a flush or heat sensation occurred with 50 mg in 10 mL but not in 20 mL.

Clinical TrialPMID: 1982983

Lack of effect of diacetyl-splenopentin (Berlopentin) on the pharmacokinetics of caffeine.

Clinical TrialPMID: 1608985

Effects of the immunomodulator diacetyl-splenopentin on antigen-induced arthritis in rabbits.

PreclinicalPMID: 1387284

Quick Facts

Class
Immunomodulatory Peptide
Tier
D
Evidence
Preliminary
Safety
Limited Data
Updated
Nov 2026
Citations
22PubMed

Also known as

SP-5Arg-Lys-Glu-Val-TyrSplenin (32-36)Thymopoietin III (32-36)DA SP-5Diacetyl-splenopentinBerlopentinBCH 069

Tags

Splenic PeptideImmunomodulatorPentapeptideResearch Peptide

Peptide Families

Related Goals

Evidence Score

Overall Confidence25%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.